| Literature DB >> 30089648 |
Nora Grahl1, Emily L Dolben1, Laura M Filkins1, Alex W Crocker1, Sven D Willger1, Hilary G Morrison2, Mitchell L Sogin2, Alix Ashare3, Alex H Gifford3, Nicholas J Jacobs1, Joseph D Schwartzman4, Deborah A Hogan5.
Abstract
Here, we report an approach to detect diverse bacterial and fungal taxa in complex samples by direct analysis of community RNA in one step using NanoString probe sets. We designed rRNA-targeting probe sets to detect 42 bacterial and fungal genera or species common in cystic fibrosis (CF) sputum and demonstrated the taxon specificity of these probes, as well as a linear response over more than 3 logs of input RNA. Culture-based analyses correlated qualitatively with relative abundance data on bacterial and fungal taxa obtained by NanoString, and the analysis of serial samples demonstrated the use of this method to simultaneously detect bacteria and fungi and to detect microbes at low abundance without an amplification step. Compared at the genus level, the relative abundances of bacterial taxa detected by analysis of RNA correlated with the relative abundances of the same taxa as measured by sequencing of the V4V5 region of the 16S rRNA gene amplified from community DNA from the same sample. We propose that this method may complement other methods designed to understand dynamic microbial communities, may provide information on bacteria and fungi in the same sample with a single assay, and with further development, may provide quick and easily interpreted diagnostic information on diverse bacteria and fungi at the genus or species level.IMPORTANCE Here we demonstrate the use of an RNA-based analysis of specific taxa of interest, including bacteria and fungi, within microbial communities. This multiplex method may be useful as a means to identify samples with specific combinations of taxa and to gain information on how specific populations vary over time and space or in response to perturbation. A rapid means to measure bacterial and fungal populations may aid in the study of host response to changes in microbial communities.Entities:
Keywords: NanoString; bacteria; clinical microbiology; cystic fibrosis; fungi; microbial communities
Mesh:
Substances:
Year: 2018 PMID: 30089648 PMCID: PMC6083091 DOI: 10.1128/mSphere.00292-18
Source DB: PubMed Journal: mSphere ISSN: 2379-5042 Impact factor: 4.389
FIG 1 NanoString detection method schematic. Frozen samples are lyophilized, and total RNA is extracted. Total RNA is mixed with the probe sets, with each containing a reporter and capture probe for each target RNA. After hybridization, the excess probes are removed and the probe-target complexes are aligned and immobilized in the nCounter cartridge. Fluorescent color sequences are counted and tabulated, yielding counts that correspond to the number of target molecules.
Taxa detected with the NanoString probe sets
| Bacterium detected | Fungus detected |
|---|---|
FIG 2 Specificity of select bacterial rRNA targeting probe sets. Control mixes were prepared with total RNA from three to five species per mix and analyzed using all of the probe sets listed on the x axis. Strain details are shown in Table S2. The probe sets for taxa not present in any of the RNA mixes (in gray font) yielded no counts above background, indicating no cross-reaction with RNAs in the mixes. All data are presented as counts, and all taxon abbreviations are defined in Table S1. The species detected by each probe set is defined by the first letters of the genus and species name, except for Streptococcus-targeting probe sets, which are abbreviated “St.” to differentiate them from Staphylococcus-targeting probe sets, which are abbreviated “S.” Probe sets that detect multiple species within a genus are indicated by “sp” as for the probe sets that detect Staphyloccocus species (S.sp), Streptococcus species (St.sp), and Burkholderia spp. (B.sp).
FIG 3 Bacterial and fungal community composition in exacerbation series from six subjects. (A) Serial sputum samples from six individuals with CF were obtained during treatment for pulmonary exacerbation and analyzed by NanoString (data in Table S3C). Microbes present in multiple subjects or abundantly in at least one subject are graphed as total counts normalized to positive controls as a stacked plot in which each segment indicates the number of counts for the indicated taxon. Bacteria and fungi are plotted on the upper and lower y axes, respectively, though the data for bacterial and fungal probe sets were obtained in the same reaction. (B) Exacerbation series E1 showed high levels of Exophiala dermatitidis by plate culture on SDA only after extended incubation.
FIG 4 Bacterial community profiles detected by NanoString and 16S rRNA gene deep sequencing (MiSeq) methods correlate and are confirmed by culture. (A) Eighteen CF sputum samples, labeled with the subject number (CF1 to -18), were analyzed by both NanoString (N) and 16S rRNA gene deep sequencing (MiSeq [S]). The percentages of relative abundance of taxa detected by both methods are shown. Only the taxa measured in our NanoString code set are included in the deep sequencing profiles, but relative abundance was determined as a percentage of total reads, not only reads represented in the NanoString code set (data in Table S4). In cases where NanoString probes detected different species within the same genus, counts from individual species-specific probes were summed to correspond with the genus-level assignments for the MiSeq data. (B) The counts for NanoString probe sets correlating with CF pathogens detected by culture are shown. See Table S3D for data for all genera analyzed. Highlighted numbers indicate that the corresponding pathogen was also detected by clinical culture analysis. The numbers in red in CF3 and CF5 were reported as being “rare” in the clinical microbiology analysis and were at very low levels (<0.5%) in the MiSeq-based community profiles for those samples. For CF sputum specimens, the clinical lab reports staphylococci only if they are identified as S. aureus.
Clinical culture report for day 0 samples from the E series
| Day 0 sample | Clinical culture report |
|---|---|
| E1 | Moderate |
| E2 | |
| E3 | |
| E4 | |
| E5 | MRSA and mucoid |
| E6 | MRSA, MSSA, and mucoid and nonmucoid |
MSSA, methicillin-sensitive Staphylococcus aureus; MRSA, methicillin-resistant S. aureus.